. Boron-Based Inhibitors of the NLRP3 Inflammasome. Cell Chem Biol. 2017 Nov 16;24(11):1321-1335.e5. Epub 2017 Sep 21 PubMed.

Recommends

Please login to recommend the paper.

Comments

  1. I don’t know how bioavailable the boron compounds will be in the CNS, but the safety profile associated with targeting NLRP3 should be quite good. There are currently five companies that have been formed to make NLRP3 inhibitors, in the hope of getting them into the clinic, although perhaps Alzheimer’s is not the first indication they will target.

    View all comments by Seth Masters

Make a Comment

To make a comment you must login or register.

This paper appears in the following:

News

  1. New AD Target: Silencing the NLRP3 Inflammasome with Boron?